Form 4: Surrozen CFO Charles O. Williams Acquires Shares and Warrants in Private Placement

Charles O. Williams, CFO and COO of Surrozen, Inc., acquired common stock and warrants through a private placement on April 4, 2024.

Summary

• On April 4, 2024, Charles O. Williams, the CFO and COO of Surrozen, Inc., acquired 1,474 shares of common stock through a private placement.
• The acquisition was made pursuant to a Securities Purchase Agreement dated April 1, 2024.
• Williams also acquired warrants to purchase common stock, including 1,474 Series A warrants, 1,603 Series B warrants, 5,712 Series C warrants, and 5,712 Series D warrants.
• The purchase price for the common stock was $16.96 per share, which includes $1.25 for the accompanying common stock warrants.
• The Series B warrants expire on the fifth trading day following the Series B Milestone Event or the fifth anniversary of the issuance date.
• The Series C and Series D warrants are exercisable for 30 days after the earlier of the occurrence of the respective milestone event or a Fundamental Transaction.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports an insider transaction. The fact that the CFO is investing in the company could be seen as slightly positive, but it's a routine filing.

Positives

• Insider participation in a private placement can be seen as a positive signal, indicating management's confidence in the company's future prospects.

Risks

• The value of the warrants is contingent on the occurrence of specific milestone events or a fundamental transaction, which may not occur.
• The warrants could dilute existing shareholders' equity if exercised.

Future Outlook

The document does not contain specific forward-looking statements beyond the terms of the warrants' exercisability and expiration.

Industry Context

This transaction is a routine disclosure of insider activity and doesn't provide significant insight into broader industry trends. However, it does indicate that Surrozen is utilizing private placements as a means of raising capital.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the reporting requirements are standardized by the SEC.
• Private placements are a typical method for biotech companies like Surrozen to raise capital, especially when seeking funding from institutional investors and management.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment due to insider participation.
• The potential dilution from warrant exercises could be a concern for existing shareholders.

Key Dates